Epigenetic Therapy Beneficial in Blood Cancers

Abstract Researchers have demonstrated that OTX015, a small-molecule inhibitor of the bromodomain and extraterminal (BET) subfamily of bromodomain proteins, shows clinical response and is generally well tolerated in patients with leukemia and other hematologic malignancies.